BriaCell is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care
Bria-IMT™, BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT™ is a targeted cell-based immunotherapy.
Bria-OTS™, a platform of personalized off-the-shelf cell-based immunotherapies, is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
How Bria-IMT™ and Bria-OTS™ Destroy Cancer Cells
BriaCell’s Patented Immunotherapy
Bria-IMT™ (for MBC)
Bria-IMT™ BriaCell Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells.
Upon achieving impressive survival and clinical benefit results in a Phase 2 study, BriaCell is conducting a pivotal Phase 3 study in metastatic breast cancer, which, if successful, could lead to full approval of Bria-IMT™ in combination with an immune check point inhibitor.
Clinical data includes unprecedented activity in heavily pre-treated MBC patients who have failed antibody-drug conjugate therapy and in patients with metastases to the central nervous system.
Off-The-Shelf Personalized Immunotherapy
Bria-OTS™/Bria-OTS+™ (for MBC, prostate cancer, and other cancers)
BriaCell’s next generation personalized off-the-shelf immunotherapy, Bria-OTS™/Bria-OTS+™, awarded numerous US and international patents and supported by clinical data of its phase 3 lead program Bria-IMT™, forms the basis of BriaCell’s “OTS” strategy. BriaCell recently initiated patient enrollment in its Phase 1/2 l bucket trial in breast /prostate/lung cancer and melanoma
- Bria-IMT™ monotherapy is most effective in HLA – type matched patients
- Bria-OTS™ is engineered to express 15 unique HLA types in 4 independent cell lines
- Provides matched treatment to greater than 99% of patients
- Simple saliva test provides HLA matched personalized off the shelf Bria-OTS™ immunotherapy
- HLA matched off-the- shelf therapy is faster and less costly than other expensive and complex personalized immunotherapies
- BriaCell received a Small Business Innovation Research (SBIR) award from the National Cancer Institute
- Ongoing collaboration with the NCI
- Bria-BRES™ Phase 1/2 study open in breast cancer.
- Bucket trial with additional cancer indications planned
- Enhanced version (Bria-OTS+™) scheduled to enter the clinic 1H2025 starting with prostate cancer
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical stage immuno-oncology company that is developing an entirely new class of targeted cellular immunotherapies to transform cancer care
- Lead drug candidate Bria-IMT™
- Pivotal Phase 3 study underway in advanced metastatic breast cancer (over 40K US deaths/year)
- Awarded Fast Track designation by FDA
- Single agent and combination check point inhibitor (+ CPI) activity
- Up to 2-fold increase in survival compared to comparable patients in the literature
- Unprecedented survival and clinical benefit even in CPI and antibody-drug conjugate (ADC) resistant patients
- Remarkable clinical efficacy data in patients with CNS metastases
- Bria-OTS™ & Bria-OTS+™: Next generation novel cell-based cancer immunotherapy platform
- Off-the-shelf and personalized
- Phase 1/2 bucket trial in breast cancer open with planned extension to prostate cancer, melanoma and lung cancer
- Next generation product candidate for prostate cancer (Bria-PROS+) scheduled to enter clinic in 1H2025
- National Cancer Institute Small Business Innovative Research (SBIR) award
- Experienced Management Team and Board of Directors; Clinical Strategy Team involved in 19 drug approvals.